JP2024510666A5 - - Google Patents
Info
- Publication number
- JP2024510666A5 JP2024510666A5 JP2023557691A JP2023557691A JP2024510666A5 JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5 JP 2023557691 A JP2023557691 A JP 2023557691A JP 2023557691 A JP2023557691 A JP 2023557691A JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165723P | 2021-03-24 | 2021-03-24 | |
| US63/165,723 | 2021-03-24 | ||
| US202163282163P | 2021-11-22 | 2021-11-22 | |
| US63/282,163 | 2021-11-22 | ||
| US202263317368P | 2022-03-07 | 2022-03-07 | |
| US63/317,368 | 2022-03-07 | ||
| PCT/IB2022/052536 WO2022200982A1 (en) | 2021-03-24 | 2022-03-21 | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510666A JP2024510666A (ja) | 2024-03-08 |
| JP2024510666A5 true JP2024510666A5 (https=) | 2025-03-31 |
| JPWO2022200982A5 JPWO2022200982A5 (https=) | 2025-03-31 |
Family
ID=80952181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557691A Pending JP2024510666A (ja) | 2021-03-24 | 2022-03-21 | Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240180906A1 (https=) |
| EP (1) | EP4313034A1 (https=) |
| JP (1) | JP2024510666A (https=) |
| KR (1) | KR20230159510A (https=) |
| AU (2) | AU2022244439A1 (https=) |
| BR (1) | BR112023018906A2 (https=) |
| CA (1) | CA3214316A1 (https=) |
| MX (1) | MX2023011294A (https=) |
| WO (1) | WO2022200982A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| JP4644737B2 (ja) | 2005-05-13 | 2011-03-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジアリールヒダントイン化合物 |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| KR101456722B1 (ko) | 2006-03-29 | 2014-10-31 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴티오히단토인 화합물 |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| NZ594741A (en) | 2009-02-24 | 2014-03-28 | Medivation Prostate Therapeutics Inc | Specific diarylhydantoin and diarylthiohydantoin compounds |
| EP2416657A4 (en) | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| WO2011044327A1 (en) | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| PT2533640T (pt) | 2010-02-08 | 2017-01-03 | Medivation Technologies Inc | Processos de síntese de derivados de di-hidropiridoftalazinona |
| NZ609490A (en) | 2010-10-21 | 2015-06-26 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| TW201605814A (zh) | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| SG11201700734RA (en) | 2014-07-31 | 2017-02-27 | Medivation Technologies Inc | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| WO2018191141A1 (en) * | 2017-04-13 | 2018-10-18 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
| KR20200071097A (ko) * | 2017-10-13 | 2020-06-18 | 메르크 파텐트 게엠베하 | Parp 억제제 및 pd-1 축 결합 길항제의 조합 |
-
2022
- 2022-03-21 BR BR112023018906A patent/BR112023018906A2/pt unknown
- 2022-03-21 EP EP22713055.6A patent/EP4313034A1/en active Pending
- 2022-03-21 AU AU2022244439A patent/AU2022244439A1/en not_active Abandoned
- 2022-03-21 MX MX2023011294A patent/MX2023011294A/es unknown
- 2022-03-21 JP JP2023557691A patent/JP2024510666A/ja active Pending
- 2022-03-21 US US18/283,634 patent/US20240180906A1/en active Pending
- 2022-03-21 CA CA3214316A patent/CA3214316A1/en active Pending
- 2022-03-21 WO PCT/IB2022/052536 patent/WO2022200982A1/en not_active Ceased
- 2022-03-21 KR KR1020237035680A patent/KR20230159510A/ko active Pending
-
2025
- 2025-07-30 AU AU2025210784A patent/AU2025210784A1/en active Pending